PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Abstract In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo)
administered in combination were evaluated as initial salvage therapy in patients with …

The objective of this guideline is to aid clinicians in making individual salvage treatment
plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN panel meets at …

The majority of patients with Hodgkin lymphoma (HL) are cured with initial therapy.
However, high-dose therapy with autologous hematopoietic cell transplant (AHCT) allows …

Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma
(HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study …

Background Brentuximab vedotin is currently approved for patients with relapsed or
refractory Hodgkin's lymphoma who previously received an autologous stem cell transplant …

Purpose This multicenter, open-label, phase II study evaluated the combination of
bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy before …

Background Patients with primary refractory Hodgkin's lymphoma or early relapse have a
poor prognosis. Although many salvage regimens have been developed, there is no …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN Guidelines …